---
import PageHero from "../../components/PageHero.astro";
import Layout from "../../layouts/Layout.astro";
import CTA from "../../components/CTA.astro";
import References from "../../components/References.astro";
import InternalNavigation from "../../components/InternalNavigation.astro";

const internalNavLinks = [
  {
    href: "#adults-changes-in-substractes",
    label: "Changes in substrates",
    active: true,
  },
  { href: "#adults-mobility", label: "Mobility" },
  {
    href: "#adults-time-to-bone-mineralization",
    label: "Time to bone mineralization",
  },
  { href: "#adults-real-world-outcomes", label: "Real-world outcomes" },
];
---

<Layout title="Adults">
  <PageHero pageId="clinical-data" classNames="clinical-data-adults__page-hero">
    <h2 class="page-hero__subtitle">
      for adults with pediatric-onset hypophosphatasia
    </h2>
    <h1 class="page-hero__title">See STRENSIQ results</h1>
  </PageHero>
  <InternalNavigation heading="Adults" items={internalNavLinks} icon={true} />
  <div class="wrapper">
    <section
      id="adults-changes-in-substractes"
      class="section clinical-data-adults--changes-in-substractes"
    >
      <div class="clinical-data-adults--col">
        <h2 class="clinical-data-adults--title">
          Change in inorganic pyrophosphate (PPi), a known inhibitor of bone
          mineralization
        </h2>

        <div class="clinical-data-adults--content">
          <p>Limitations:</p>
          <ul class="clinical-data-adults--list">
            <li>
              One of the coprimary endpoints of this study, change in PPi at 6
              months, did not reach statistical significance when comparing the
              control group to the treatment group. For the total cohort,
              within-subject changes in both pyridoxal 5’-phosphate (PLP) and
              PPi were observed after 6 months and over 5 years of treatment
            </li>
            <li>
              The control group began treatment 6 months after the treated
              group, with baseline considered the last assessment before first
              dose
            </li>
          </ul>
        </div>
      </div>

      <div class="clinical-data-adults--col">
        <img
          class="clinical-data-adults--img"
          src="/assets/images/clinical-data/adults/PPi_Adults.png"
          alt="PPI Adults"
        />
      </div>

      <div class="clinical-data-adults--col">
        <h2 class="clinical-data-adults--title">
          Change in pyridoxal 5’-phosphate (PLP), the active form of vitamin B6
        </h2>
        <div class="clinical-data-adults--content">
          <ul class="clinical-data-adults--list">
            <li>
              Change in PPi and PLP data are from the open-label extension phase
              of the study, which included 19 adult and adolescent patients
              <ul>
                <li>
                  Of the 13 adult patients, 12 had pediatric-onset
                  hypophosphatasia
                </li>
                <li>
                  Three adults were part of the untreated group during the
                  primary phase
                </li>
              </ul>
            </li>
            <li>
              Over the initial duration, the study used lower doses of STRENSIQ
              than those in the current FDA-approved label
            </li>
            <li>
              The most common adverse events reported in the adult population of
              Study 4 were injection site reactions, similar to what was
              observed in clinical trials
            </li>
          </ul>
        </div>
      </div>

      <div class="clinical-data-adults--col">
        <img
          class="clinical-data-adults--img"
          src="/assets/images/clinical-data/adults/Median_PLP_Adults.png"
          alt="PLP Adults"
        />
      </div>
    </section>
  </div>
  <CTA
    heading="Get the blueprint for STRENSIQ dosing"
    linkText="Dosing"
    linkUrl="/dosing"
  />
  <References />
</Layout>
